After observing the antagonistic relationship between BAP1 and SIRT1, particularly in their convergence on the K80 acetylation of HSF1, we became intrigued by the potential efficacy of combining SIRT1 inhibition with ICB therapy in models of pancreatic cancer characterized by BAP1 deletion. This evidence concerns the gene HSF1 and pancreatic neoplasm.